Eisai Plans to Present Five-Year Lecanemab Data at CTAD
Eisai plans to present five-year lecanemab study data at the CTAD conference.
Related stories
Campari Reports Q3 Revenue of €777 Million, Shares Fall 6.43%
Revenue rose 3.3% organically and exceeded the €769 million consensus estimate. Campari confirmed its full-year organic revenue growth guidance of 3%, citing weakness in North Amer
M impact | EQUITY | Oct 29, 2026, 05:03 PM UTC
Netcompany Group Reports Q3 Revenue Growth and Raises Guidance
Q3 2026 revenue rose 8.1% year over year to DKK 2,343.8 million, while adjusted EBITDA increased 16.9% to DKK 420.1 million. The company raised its full-year revenue growth guidanc
M impact | EQUITY | Oct 29, 2026, 05:03 PM UTC
Ambuja Cements Q2 Profit Falls 90% to Rs 236 Crore
Consolidated profit after tax fell 90% year over year to Rs 236 crore in the July–September quarter of FY27, compared with Rs 2,336 crore a year earlier. Revenue from operations st
M impact | EQUITY | Oct 29, 2026, 05:03 PM UTC
IndiGo Reports Rs 1,879 Crore Q2 Loss as Revenue Rises 25.9%
InterGlobe Aviation reported a consolidated net loss of Rs 1,879 crore for the September 2026 quarter. Revenue rose 25.9%.
M impact | EQUITY | Oct 29, 2026, 05:03 PM UTC
Suzlon Energy Q2 Revenue Rises 26% to Rs 4,869 Crore
Suzlon reported record quarterly deliveries of 710 MW and an order book above 6 GW; EBITDA margin declined year on year.
M impact | EQUITY | Oct 29, 2026, 05:03 PM UTC
Jupiter Wagons Wins Rs 1,140 Crore Order for 2,583 Wagons
Jupiter Wagons secured a contract from India's Ministry of Railways to manufacture and supply 2,583 wagons. The company projects incremental inflows of Rs 2,000 crore in Q4 FY27.
M impact | EQUITY | Oct 29, 2026, 05:02 PM UTC